Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - rifabutin, quantity: 150 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; magnesium stearate; silicon dioxide; iron oxide red; titanium dioxide; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid; povidone; tert-butyl alcohol; sodium hydroxide - mycobutin is indicated for: the prophylaxis of m.avium-intracellulare complex (mac) infections in patients with advanced hiv infection (cd4 counts lower than 200/ul); the treatment of infections caused by mac and other atypical mycobacteria, including in immunocompromised patients; the treatment of chronic multi-drug resistant pulmonary tuberculosis in the presence of rifampicin resistant, rifabutin-sensitive m.tuberculosis strains; the treatment of newly diagnosed pulmonary tuberculosis in the presence of rifampicin resistant, rifabutin sensitive m.tuberculosis strains. in accordance with the commonly accepted criteria for the treatment of mycobacterial infections, mycobutin should always be given in combination with other anti-mycobacterial drugs not belonging to the family of rifamycins.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - rifabutin - capsules - rifabutin 150 mg - rifabutin - rifabutin - for the treatment of chronic tuberculosis where there is evidence of acid fast bacteria resistant to rifampicin or to two other alternative drugs. for the treatment of infections caused by mac or other atypical mycobacteria where there is evidence of resistant bacteria as above. for the treatment of infections caused by mac or other atypical mycobacteria in aids patients in all cases not subject to the above restrictions. for prevention of mac infections in aids patients whose cd4 counts lower or eqval to 200/mm3

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - rifabutin -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - rifabutin - oral capsule - 150mg

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - rifabutin (unii: 1w306tda6s) (rifabutin - unii:1w306tda6s) - rifabutin 150 mg - mycobutin capsules are indicated for the prevention of disseminated mycobacterium avium complex (mac) disease in patients with advanced hiv infection. mycobutin capsules are contraindicated in patients who have had clinically significant hypersensitivity to rifabutin or to any other rifamycins.

United States - English - NLM (National Library of Medicine)

department of state health services, pharmacy branch - rifabutin (unii: 1w306tda6s) (rifabutin - unii:1w306tda6s) - rifabutin 150 mg - mycobutin capsules are indicated for the prevention of disseminated mycobacterium avium complex (mac) disease in patients with advanced hiv infection. mycobutin capsules are contraindicated in patients who have had clinically significant hypersensitivity to rifabutin or to any other rifamycins.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - rifabutin (unii: 1w306tda6s) (rifabutin - unii:1w306tda6s) - mycobutin capsules are indicated for the prevention of disseminated mycobacterium avium complex (mac) disease in patients with advanced hiv infection. mycobutin capsules are contraindicated in patients who have had clinically significant hypersensitivity to rifabutin or to any other rifamycins.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - rifabutin (unii: 1w306tda6s) (rifabutin - unii:1w306tda6s) - rifabutin 150 mg - mycobutin capsules are indicated for the prevention of disseminated mycobacterium avium complex (mac) disease in patients with advanced hiv infection. mycobutin capsules are contraindicated in patients who have had clinically significant hypersensitivity to rifabutin or to any other rifamycins.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - rifabutin 150mg - capsule - 150 mg - active: rifabutin 150mg - mycobutin is indicated for infections caused by mycobacteria, such as m. tuberculosis, m. avium intracellulare complex (mac) and other atypical mycobacteria. in infections caused by mac and other atypical mycobacteria such as m. xenopi, mycobutin has been shown to be effective for the treatment of both disseminated and localised disease, also in immunocompromised hiv positive patients. mycobutin is also indicated for the prophylaxis of m. avium intracellulare complex (mac) infections in immunodepressed patients with cd4 counts lower than or equal to 100/ml. in the treatment of tubercular disease, mycobutin has been shown to be effective for the treatment of patients with chronic pulmonary tuberculosis, even if caused by multidrug-resistant m. tuberculosis strains. in accordance with the commonly accepted criteria for the treatment of mycobacterial infections, mycobutin therapy should always be given in combination with other antimycobacterial drugs not belonging to the family of rifamycins.

Malta - English - Medicines Authority

health house pharma ltd t/as p&d pharmaceuticals ltd 38 woolmer way, bordon, hampshire, gu35 9q, united kingdom - rifabutin - hard capsule - rifabutin 150 mg - antimycobacterials